Progyny, Inc. (PGNY) Earnings Call Transcript & Summary
November 4, 2026
Earnings Call Speaker Segments
James Hart
executiveThanks, Sylvie, and good afternoon to all of you. We're glad you could join us for this third quarter conference call. Joining me are Pete Anevski, Progyny's CEO, and Mark Livingston, our CFO; we'll start with some prepared remarks, and then we'll take your questions. Before we get going, I want to note that what we say and how we answer your questions today reflects management's views only as of today, and it will include statements about: our financial outlook for the fourth quarter and for the full year 2026, along with the assumptions and drivers behind that guidance; demand for our solutions; what we expect from our selling season for 2027 launches; anticipated employment levels at our clients; the industries we serve; when client decisions are expected; our expected utilization rates and mix; the potential benefits of our solution; our ability to bring on new clients and to retain and upsell existing ones; our market opportunity; and our business strategy, plans, goals, and expectations regarding our market position, future operations, and other financial and operating information—all of which are forward-looking statements under the federal securities law. Actual results could differ materially from those contained in or implied by these forward-looking statements because of risks and uncertainties associated with our business, as well as other important factors. For a discussion of the material risks, uncertainties, assumptions, and other important factors that could impact our actual results, please see our SEC filings and today's press release, both of which are on our Investor Relations website. Any forward-looking statements we make on this call rest on assumptions as of today, and we undertake no obligation to update these statements as a result of new information or future events. During the call, we'll also refer to non-GAAP financial measures, such as adjusted EBITDA. More information about these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, is available in the press release, which you can find at investors.progyny.com. I'd now like to hand the call over to Pete.
Pete Anevski
executiveThanks Jamie, and good afternoon everyone — appreciate you joining. We’re glad to report that Progyny had a robust quarter, posting record revenue and profitability for Q3, while also continuing to produce substantial cash flow. That cash is being used in two ways: investing in the business to support future growth, and returning value to shareholders via meaningful share repurchase activity. Looking ahead to Q4, member engagement is still healthy. Given that, and with our strong results over the first nine months of the year, we’re pleased that we can raise the midpoint of our full-year guidance. Mark will take you through the specifics soon, including the quarter’s highlights. I'll spend my time this afternoon walking you through the results from our latest selling and renewal season, because those areas make the biggest contribution to our longer-term growth trajectory. We're extremely happy with how this selling season turned out, producing a record 1.3 million new covered lives along with more than 85 new clients. These excellent results begin with ongoing macro demand from plan sponsors for this critical benefit, and they're fueled by execution across the board in all of our go-to-market strategies and teams. This year's season once again demonstrates how significantly our solutions stand apart from alternatives in the market. Let me use the rest of my time today to break down that headline. Each selling season begins with several goals for us: bringing in new logos and lives, keeping the base we already have, and strengthening ties with current accounts by growing the services they use with Progyny. In all three of those areas this year's season, we again hit or surpassed our targets. Starting with acquiring new clients — all year long, we've discussed the encouraging activity we were seeing there. We credit this momentum to a few areas we expect to persist past this selling season. The first is that employers see family building and women's health as a key priority. We're tackling medical needs that are both genuine and widespread — needs that, if poorly handled, can prove expensive and even damaging to a company's workforce. Indeed, several analysts have highlighted this topic in recent research reports, since market surveys and calls with key opinion leaders keep confirming that these programs rank among the top priorities for HR leaders; and everyone knows employers and members are facing some of the steepest costs and trends seen in decades. Employers want more from their partners, seeking to bring costs down and keep trends in check, while still expecting the best possible quality outcomes and member experience. Firms keep using demanding processes to identify the right solutions meeting those criteria. Progyny could show it delivers on those commitments, and a demonstrated history across every critical area set our offering apart from rivals in the eyes of these selective purchasers time after time. Those buyers cared about value, controlling costs, results, and the member experience, and those priorities drove the momentum we experienced throughout the entire season. It began in the very first days as the pipeline was growing, continued through summer and autumn, and even extended into the last part of the season, as evidenced by the additional 100,000 lives—which arrived only since the expectations update we released a month ago. Activity this season wasn't limited to one region, one sector, or one category of client. Instead, the wins we posted this year reflect one more varied slice of the economy, just as has been true for many years now. Among our newest clients are a number of the country's most prestigious universities, an additional Mag 7 technology leader, a bank that ranks among the biggest in the U.S., and the largest health benefit fund for public employees in the nation. The group is also spread widely across client size, with the newest logos bringing in anywhere from 1,000 to far more than 100,000 lives, which underscores all the more how universally relevant and appealing our services are. So we enter 2027 with the widest-ranging client roster in our history, and no individual sector of the economy and no individual client accounts for a disproportionate portion of our book. This newest cohort is also joining at the customary coverage levels we've seen for a long time, averaging two to three smart cycles. Among these new clients, our pharmacy offering has reached an attach rate close to 100%, which once again underscores the value and differentiation of Progyny Rx for both the patient and the plan sponsor relative to the alternatives. On the alternatives side, competition remains lively, yet we continue to observe signs that some rationalization is taking place. Among the models that might not be profitable, might not operate at scale, or haven't managed to keep cost trends in check, one company left the market altogether twelve months ago, and at present we're seeing a second one scale back considerably. These signals suggest a market that works properly, with capital flowing toward models with demonstrated success—ours included—and what we delivered this season makes clear how strongly employers want a solution with a proven track record. To be clear, although what we learned from competitors added a helpful contribution to our results, it was not an outsized force behind this season's success. Rather, the season mirrors the convergence of several of our strategies — among them the advancement of our channel partners, in particular our relationship with Cigna as our national partner, along with the largest regional plans, disciplined management of our go-to-market strategies and resource allocation, and our capacity to respond successfully to where the market stands by continuing to invest in our solution, so that the value we deliver is beyond question when we walk these prospects through our solution in detail. Consistent with prior commitments and as we had anticipated, Progyny Select—our latest product for the fully insured market—made only an immaterial contribution to the results of this season. Since this marks our first year with that program, we have concentrated on developing the relationships and the infrastructure needed to scale it meaningfully over time. Given the progress we made on both fronts this year, along with the feedback coming from the market, we still expect Select to become a key element of our longer-term growth. Now regarding the rest of our selling-season priorities, retention and expansions: as we noted earlier this year, we reduced retention risk by securing early commitments from our biggest accounts in a renewal year, and that positive momentum continued through the rest of the season, delivering another year of retention close to 100% across the existing base. In addition, about 20% of the base has chosen to expand their solution in some way for 2027; that number includes clients who decided to consolidate with Progyny the other women's health service components that competitors had previously handled for them. Looking ahead to the coming season, we feel our position is unusually strong for carrying this year's momentum forward into 2027; as we close out the year, our setup for the season ahead is the best we have ever had, measured both by how many opportunities exist and by the pipeline's overall size and quality, which tells us that market momentum this year is benefiting not just the current selling season but the next one too. And to wrap up, on top of all that, we are enthusiastic and entering the upcoming 2027 season with sales momentum stronger than at any point in our history. I'll now turn the call over to Mark, who will take you through the results in more detail.
Mark Livingston
executiveThanks, Pete, and good afternoon, everyone. First, a quick note: the 8-K filed this afternoon contains the usual slides that summarize our quarterly results, and that material is also up on our website. Instead of going through those slides again, I'll spend my time today on the longer-term trends we see as most important for understanding how healthy the business is and where it's headed. Let's get started. Member engagement has stayed within the ranges we've long established, and utilization this quarter trended toward the upper end of those ranges. The somewhat sharper seasonality we mentioned last quarter turned out, as expected, to be short-lived, and it has gone back to what we'd normally expect as fall got underway. We think this shows once more that members seek out the care and services they need, and they do so when the timing works for them. Because of that, revenue for the quarter came in above the midpoint of our guidance, up nearly 9% compared with 2025. Across the first nine months of the year, revenue rose 11% if you exclude the contribution from a large former client that had a transition of care agreement in place through the first half of 2025. Alongside that solid growth, we've kept our margins healthy overall, even while we keep investing to broaden our product platform, improve the member experience with new features, and build the foundation for growth ahead. Gross margin was up 130 basis points from the third quarter of last year, driven by lower stock compensation expense and by the efficiencies we keep achieving in delivering our care management services. It's worth pausing to highlight those efficiencies. For years, we've used the growing scale of our volumes to offset the pressure that broader medical cost inflation puts on program rates. While we may keep some of those savings to expand margin, we also pass a share along to our clients, which adds to the value we already deliver through disciplined program management and our superior clinical outcomes. Adjusted EBITDA margin came in slightly below a year ago. Even so, measured on a trailing 12-month basis, adjusted EBITDA margin stood at 17.1%, in line with how it has trended through this period of heavier investment, which shows we can invest for growth without needing to reset our overall profitability levels. On those investments: CapEx year-to-date runs roughly $9 million above what we spent in the first three quarters of 2025, though it's still a relatively modest level at about 2% of revenue. Through disciplined, prudent management of the business, we've also kept achieving strong conversion of adjusted EBITDA into operating cash flow, and we've continued to hit, and even surpass, our 75% conversion target, both in the third quarter and year-to-date. This quarter we generated over $56 million of operating cash flow, which works out to $207 million on a trailing 12-month basis. So with that result, we've now topped $200 million in operating cash flow on a trailing 12-month basis across seven quarters in a row, which shows how consistent our performance has been and also how strong and adaptable our business model is. We kept pushing an improvement in DSO as well, thanks to our sustained attention to the processes that turn revenue into cash. DSO finished the third quarter almost seven days below the prior-year figure, landing at just under 66 days. We'll always look for further gains, but we do think we're approaching the point of maximum yield, given how dependent we are on health plan claim processing. At September 30th, total working capital stood at $224 million, including $196 million of cash, cash equivalents, and marketable securities. We had nothing drawn on our $200 million revolving credit facility and no debt whatsoever, and at present we have no plans to use that facility. The drop in our cash balances since June mirrors the substantial share repurchase activity we carried out during the quarter. Under our latest $200 million authorization, we bought close to 3 million shares in the third quarter for roughly $83 million. Since that authorization started in May, and counting activity after September 30th as well, we've repurchased a cumulative total of nearly 5.5 million shares under the newest program, with about $51 million still available for future purchases. Taken together — this current program plus our earlier $200 million program, which wrapped up earlier this year — we've now bought back over 14 million shares in total since last November. That has cut our overall shares outstanding by almost 15% during the past year. Now to what we expect for the fourth quarter and the rest of 2026. Most of the over 85 clients and 1.3 million lives added in the latest selling season should go live in the first quarter of 2027, although a meaningful number of lives — several hundred thousand, give or take — are slated to launch midyear. Beyond that, a small number of the newest clients have already launched their benefit in 2026. When all the new clients are live in 2027, we expect to have over 660 clients representing 8.3 million covered lives. As the fourth quarter gets underway, member engagement is holding up well and tracking with past patterns. So our expectations for engagement metrics stay in line with our earlier assumptions. The table at the back of today's press release lays out those assumptions at both ends of the full-year guidance ranges. With the consistency in engagement we've observed and the strength of our results through the first three quarters, we're glad to raise the midpoints of our guidance for the year; we now expect full year revenue of between $1.365 to $1.385 billion, which reflects growth of 5.9% to 7.5%. When you remove the $48.5 million of revenue generated in the first half of 2025 by a client operating under a transition of care agreement, our projected revenue growth for the full year comes to 10.1% to 11.7%. Turning to profitability, adjusted EBITDA is expected to land between $235 million and $240 million, with net income in the range of $107 million to $110.6 million. That works out to $1.30 to $1.35 of earnings per diluted share, and $2.09 to $2.13 of adjusted EPS, assuming roughly 82 million fully diluted shares. For the fourth quarter, revenue is expected to come in at $344.7 million to $364.7 million, representing growth of 8.3% to 14.6%, which reflects how we see engagement shaping up in the quarter. On the profitability side for the quarter, we anticipate adjusted EBITDA of $57.9 million to $62.9 million, together with net income of $28.5 million to $32.1 million. That translates to $0.36 and $0.41 of earnings per diluted share, or $0.53 and $0.58 of adjusted EPS, based on 79 million fully diluted shares. Looking at the midpoints of the ranges for both the quarter and the year, you'll note that we anticipate holding a steady adjusted EBITDA margin despite the investment we're making to grow the business. With that said, we'd now like to open things up for questions. Operator, could you please give the instructions?
Jailendra Singh
analystThank you, and I appreciate you taking my questions. Congratulations on such a strong selling season. Thanks for the detail on how the rollout splits between 1/1 and midyear. My assumption is that the midyear rollout likely ties to the CalPERS contract, which has drawn quite a bit of attention. Drawing on your past experience, would it be fair to say that the economics or the expected utilization for a large public sector client would differ at all from what you'd see with an average client in a new cohort? I'm just trying to get a handle on the economics of this new contract.
Pete Anevski
executiveSure. Thanks, Jailendra. On the economics, from a margin profile standpoint, we anticipate consistency with our business — I'll begin there. When it comes to the utilization rate for that population, they gave us a tremendous amount of data, and through our underwriting process, we anticipate somewhat lower utilization than our typical book of business for that population. In line with that expectation, that's the basis on which we underwrote it, and that's how we anticipate the overall margin profile will look for that client.
Jailendra Singh
analystAll right. For my follow-up, and broader than that, still on this same margin subject: in the past you mentioned that heavier investment cycles ought to start easing in 2027. Meanwhile, you keep finding efficiencies in how care management is delivered, and on top of that a record selling season is about to arrive. How should we weigh reinvestment against letting more of that incremental gross profit reach EBITDA — I'm just attempting to grasp whether 2027 ought to be a year in which margins expand for you folks?
Pete Anevski
executiveYes. Once we report year-end results, we'll lay out expectations via full year guidance for 2027, yet what we've already communicated regarding our tapering investments across 2027 remains the expectation.
Jailendra Singh
analystGreat, thanks very much.
Scott Schoenhaus
analystHi, everyone. Appreciate you taking my question, and congratulations on the 100,000 additional lives since the last announcement. Pete, you talked about how you stand apart in the market compared with other competitors we keep hearing about this year versus prior years. Could you maybe discuss the competitive conversations or the conversions you witnessed this selling season, what's still out there in the market, and the ones you're having active conversations with? To be specific, we all know of the large employer, in fact the largest employer, which I think you referenced in your comments, has seen some challenges with their fellow fertility benefit partner. Do these big employers still want to engage? Are they approaching you directly? I'm just trying to gauge how these prospects look on your platform compared with what else is available in the market. Thanks.
Pete Anevski
executiveI'll do my best to address each of your points, and if anything gets left out, just come back to me. On the sales process and how we stand apart in the market, two things really matter: first, when you examine all the solutions closely, there is meaningful differentiation across every aspect of what we offer compared with other alternatives out there. The way big employers—and really all employers, though larger ones typically take a more thorough approach—dig into the details makes that distinction stand out, and they value it. Another crucial piece is how we've shown we can consistently perform, delivering on outcomes and keeping costs in check as time goes on, which matters especially when medical cost inflation is a concern. Choosing a really significant benefit—whether you're layering it on or swapping out what you currently have—happens against a backdrop of steeply climbing costs elsewhere across healthcare. Picking Progyny feels good, since in our view you're getting the top solution on many fronts, and one that has proven, year after year, that it keeps costs under control. That question had another part to it.
Scott Schoenhaus
analystI suppose on the competition front, right, you've discussed the competitive landscape quite a bit, and I'm assuming you've witnessed plenty of competitive conversions during this selling season, so maybe you could speak to that and what's still left out there; we're all aware of the biggest employer out there that has had a fertility provider which has run into some challenges, and I'm wondering whether you're having conversations with these very large employers that are in the market here. Yeah.
Pete Anevski
executiveYes, that's right — we had conversations with clients who were at competitors. Yes, we saw those clients convert from across our competitors. The key part of that, though, is that this isn't the biggest driver of our sales year overall. Our sales year overall contributed because we hit all of our different go-to-market strategies and the teams executed very effectively; now, when it comes to that large employer you're referring to, we do get the chance from time to time to talk with them. There are other large opportunities currently active in our pipeline that I mentioned as setting us up for this 2027 sales season as well. I would never stake everything on any single opportunity. What I think is the more important point you should take from my comments is how we're set up overall and our overall active pipeline for next year, with many large opportunities already in place.
Scott Schoenhaus
analystAll right, I'll rejoin the queue. Thanks for taking that question, Pete.
Pete Anevski
executiveThanks.
Stan Berenshteyn
analystHey there, thanks — this is Stan. I believe Scott spoke ahead of me, but regardless, I appreciate the questions. Perhaps starting with the guidance: ART cycles came in fairly level quarter over quarter. It looks like 4Q needs somewhat of an uptick on a sequential basis. So could you share your view on visibility at this point, given we're maybe a third of the way through the quarter?
Mark Livingston
executiveWell, I'd say some of this simply reflects the modest deceleration we experienced in the third quarter, and as we mentioned, that typically starts to reverse in September and then carries into October. From where we sit right now, visibility is quite strong for October and also into November. We're observing those patterns returning to more normal, healthy levels as we move into Q4, and that is essentially the foundation for our guidance.
Stan Berenshteyn
analystUnderstood. So I just have one more question about the sales pipeline: clearly you had a strong season this year. Could you perhaps speak to how the sales pipeline is composed as we look ahead to next year, at the top of the funnel? Has anything shifted regarding what you expect next year's selling season to look like? Thank you.
Pete Anevski
executiveJust as we always do, and just as we're doing right now, we'll share commentary — not only today, but also on our year-end earnings call, when we'll have greater visibility into the pipeline overall and into how the selling season is shaping up. That said, as things stand right now, as I mentioned in my prepared remarks, our active pipeline — which, again, the way I always discuss pipeline, is defined by specific activity tied to sales progression on those accounts — is larger than it has ever been at this point in time, including versus last year. That's why I say we're very well positioned overall in active pipeline, including with a number of jumbo accounts that sit in that active pipeline for next year. Past that, I really can't offer any further color commentary that would be constructive, really, until the year-end call in February.
Stan Berenshteyn
analystUnderstood. Many thanks.
Constantine Davides
analystThanks. I have a couple of questions if I may. Pete, I believe you mentioned that 20% of the base expects to add to their benefits in '27. Could you say more about how that expansion trend compares with the last couple of years? And then second, I think you noted a 100% attach rate on new business for next year when it comes to pharmacy. Can you describe how that looks for some of the newer solutions you've launched in recent years, and what that attach rate is on that 1.3 million lives? Thanks. Yeah.
Pete Anevski
executiveOn the first part of your question, that 20%, and those are sales commitments tied to upsells with existing clients, is broadly consistent with what we've seen over the last couple of years. The second part, on the Rx, the attach rate with the Rx is very positive, in line with what's occurred across the last couple of sales seasons, in which the significant majority of all new clients are adding Rx. I think we now expect roughly 96% of clients next year to have Rx overall, 95%, 96%; then the last part of your question is that the attach rate of the expanded products beyond Rx was positive once again this year, and we'll now have more than 3 million lives with the expanded products beginning during 2027.
James Hart
executiveAll right. Sylvie, you’re next.
Michael Cherny
analystHello.unclear question,and congratulations on the robust selling season. Perhaps returning to the summer seasonality discussed last quarter, could you elaborate a bit more on how engagement got back to usual levels, and was that just a shift toward more typical activity, or did you observe some of the treatments postponed over the summer returning?
Mark Livingston
executiveApologies, I believe the start was slightly cut off, if you wouldn’t mind.
Pete Anevski
executiveI guess my question is about the seasonality we saw in Q3 — did that come back to normal levels, or more simply, can you just comment on whether things are back to normal levels?
Mark Livingston
executiveAs the quarter wrapped up, we observed somewhat heavier utilization—though not yet any movement toward ART cycle treatments—and utilization was a little elevated as we exited the quarter and headed into Q4; October, as usual, tends to be a really strong month for us across the board. That progress has come in as we anticipated, and regarding mix and so forth, it's again consistent with what we'd normally expect. As I believe I mentioned in my remarks a few minutes back, we have solid visibility through October and into November, and that is what our guidance takes into account.
Michael Cherny
analystThanks.
Cameron Harbilas
analystHello, Cameron Harbilas here, filling in for Brian Tanquilut. Congratulations on the quarter, and I appreciate you taking my question. Could you share a bit about what you picked up during your first selling season working with Cigna as a partner? I realize you mentioned that it generated considerable growth, though not an outsized amount. Was there anything new you took away from it? And then just refresh us on how the selling process differs between a partner-led deal and a competitive takeaway?
Pete Anevski
executiveI'm not certain we picked up anything major that was new, but the same kind of activity you'd engage in when working alongside your consulting partners who advise their clients is the same kind of activity that supported sales efforts through Cigna's clients, when we collaborate with their account executives, as one simple example. That, along with the places where opportunities existed on the operations side to assist with integrating these clients into our systems and Cigna's systems, are all factors that generated positive activity throughout the Cigna organization.
Cameron Harbilas
analystGreat. So just as a quick follow-up, can you give us an update on where you stand regarding getting the complete eligibility files from your client base? I know that earlier in the year you set a goal of having a significant majority of those by year-end.
Pete Anevski
executiveBy year-end, eligibility files ought to cover over half of our lives.
Cameron Harbilas
analystThank you.
Pete Anevski
executiveI'd like to point out that utilization does fluctuate a bit from time to time. I wouldn't necessarily read too much into what we've seen so far this year — and the year isn't finished yet — regarding what will happen next year; we simply don't have visibility that far ahead when it comes to actual utilization. When we report at year-end and discuss guidance for 2027 on our February call, we do comment on what we're seeing at that point regarding utilization; that's the earliest we could give you any genuine insight into what we're seeing so far for utilization rather than sort of speculating about it now. Again, utilization looks good, and as Mark said, overall utilization came in a little stronger than we had expected for Q3; as for ART cycles per utilizer, they were pretty much in line with our expectations, and more importantly, as we discussed, starting here in the fall for Q4, it's what we would expect. Got it, thank you. Then just a quick, maybe administrative question here: I noticed the member base is down just slightly quarter-over-quarter. I know these administrative true-ups happen once in a while — was that the case in 3Q as well? Anything else you'd like to comment on that? Did you hear that whole question?
Mark Livingston
executiveEvolved
Pete Anevski
executivewhat?
Mark Livingston
executiveRight. So I'd say membership is basically where it was before. At this stage we're talking about very small percentages. There's no trend there worth reading into. Understood. Thanks.
Sarah James
analystThanks. You mentioned that savings from care management might be kept as a tailwind for gross margins or else shared with clients. What decides that division, and has the portion going to clients increased now that employers face growing cost pressure?
Mark Livingston
executiveSarah, honestly this is something we've done since inception, and what I was really pointing out is that over the long run, as our scale has grown, we've managed to keep costs flat, and in some cases lower them across many years. The key point is that, alongside the favorable outcomes and other savings we deliver for clients, we're also very focused on their costs and pricing. You'll notice our gross margins have improved somewhat over time, but part of that really reflects the fact that we obviously want to balance returns for shareholders too. Look, we're aware of where our clients stand and the kinds of cost increases they're seeing from their other plans, but as you can see, even in that environment, we've kept expanding our margins a little. Nothing I'd flag there. Pete, I don't know whether you'd like to add anything.
Pete Anevski
executiveI think the key thing on that — and we put this out, I can't recall which conference it was, James, at J.P. Morgan — is that across a 3-year stretch, costs rose just 1% to 2% per year. That reflects the leverage we keep generating as we expand throughout the network, which lets us hold costs in check even with the other difficulties, as I've mentioned previously, and as we all witness nationwide, given what medical cost inflation is doing. I think our retention rate and the clients say a great deal about it. Clients value that reality a lot, and at the same time we keep providing genuine value when it comes to outcomes, plus overall savings stemming from those outcomes and a favorable member experience that we keep delivering on.
Sarah James
analystThat's excellent. If I could squeeze in one more: clearly you had a very strong selling season, with 1.3 million new lives. What portion of that comes from brownfield versus greenfield, and does that change what first-year utilization usually looks like?
Pete Anevski
executiveYeah. The split between them is fairly even — a bit more brownfield than greenfield, but fairly even. No, utilization isn't affected by that. Industry is what affects utilization more, but for that overall population of 1.3 million, we don't anticipate anything significantly different when it comes to utilization.
Mark Livingston
executiveKeep in mind that we defined brownfield as having any kind of fertility benefit whatsoever, but once again, we think most of those other plans don't offer comprehensive coverage, so this isn't truly a case of someone moving from comprehensive coverage to comprehensive coverage; when they come to us, it's a step up.
Sarah James
analystThanks.
Peter Warendorf
analystHello, and thanks for asking. With the selling season basically behind you folks now, I wanted to ask about fiscal '27. It appears membership will be up around mid-teens in the coming year. It sounds as though a few hundred thousand of those lives may begin around midyear, and some offset could come from upsell within the existing membership base. So I suppose my question is whether membership growth is a fair baseline as we begin thinking about next year, and should we also consider any other significant puts and takes? Thank you.
Pete Anevski
executiveThere aren't any I'd point to at this time. The lives are the major variable, in my view, and clearly our expectations match what I just described regarding this cohort. When we lay out guidance for 2027, we always wait to observe how early utilization appears during the year. Should anything else warrant mention at that point, we will do so, but beyond that, there really aren't other significant puts and takes compared with what could be a major driver next year.
Peter Warendorf
analystGreat. Thanks.
David Larsen
analystHi there. It seems your gross margin has improved quite a bit, up over 100 basis points compared with a year ago. In our model we're assuming roughly a 25% gross margin. How high could that go over time? And on SG&A, we're modeling a 15% decline year-over-year. That's impressive. Where are those savings coming from, and what do you expect for your EBITDA margin longer term? Thank you.
Mark Livingston
executiveBoth of those items, or rather both questions, tie in some measure to stock comp expense. For several years now we've been anticipating that grants made in a number of past years, from an expense accounting standpoint, would roll off, some late in '25 and more here in '26. If you look, and we include it in the release, if you view it on an excluding stock comp basis, the growth in gross margin is somewhat more moderated, as are the changes in the OpEx lines. In fact, when you look at the OpEx lines, you'll see there's actually been some investment year-over-year in SG&A, both for our go-to-market resources and for the platform expansions we've discussed over the last several quarters.
David Larsen
analystWhat is your targeted EBITDA margin over the long run?
Mark Livingston
executiveThere isn't a target we've shared publicly with the market. We have talked about expansion across the various parts of the business, whether that comes from new products we've launched or from Progyny Select, and our statement has been that we anticipate those margins will be similar. Now, as we start to wind down the spending we've undertaken over the past couple of years on certain integrations involving companies we acquired, along with our platform, we do anticipate getting back to incremental margins as we expand, though we have not yet released an official figure for that.
David Larsen
analystJust one final quick question: could you speak to the wider macro trends and what effect they're having on demand? Demand looks great, but we've still got inflation that's relatively high, medical trend is really high, and you still have a fairly high prevalence, or a rising prevalence, of GLP-1 users, which aren't cheap, and those are pushing medical costs up. It seems to me there would be a lot of competing costs for your clients, yet you still see great growth. Any thoughts on that would be very helpful. Thank you.
Pete Anevski
executiveSure. In a setting where medical cost inflation is exactly what you described, continues, and is projected to stay high next year, set against the reality that incidence and prevalence for infertility remains 1 in 5 per the CDC, very, very prevalent as an area of healthcare that has to be covered. At some point you do have to make a decision to cover this benefit, whether you already cover it and it isn't comprehensive enough, or you're seeking a new solution doing a better job, or you don't cover it at all. That, we believe, is what drove our sales, right? Ultimately, when you have to make that decision, add that expense and/or manage that expense, you want to do it in a way that's most effective from a cost perspective, with the best member experience and outcome and savings. That resonated in the market. Although you're right, mindshare out there is being shared relative to these other drivers that exist, the conversation is still very robust relative to needing this benefit, especially when you consider that it addresses the millennial population, which is the largest population of your workforce today.
David Larsen
analystExcellent, many thanks. Congratulations on a solid quarter.
Pete Anevski
executiveThanks.
Mark Livingston
executiveThanks.
James Hart
executiveThanks, Sylvie, and thanks to all of you for being with us this afternoon. Our hope is that this call proved useful to you. As ever, don't hesitate to get in touch with me if you require any additional help. We're glad to talk. If not, we hope to see you at the conferences coming up.
Operator
operatorThanks. That brings us to the end of today’s conference call. At this point you’re welcome to hang up your phone lines, and we hope you have a wonderful evening. We appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Progyny, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Progyny, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Progyny, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.